Akari Therapeutics (AKTX) Free Cash Flow (2014 - 2026)

Akari Therapeutics (AKTX) has reported Free Cash Flow for 9 consecutive years, with -$2.5 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow fell 15.72% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.9 million (down 2.33% YoY) and the FY2025 annual result came in at -$10.6 million, up 15.81% from the prior year.
• Free Cash Flow improved to -$2.5 million in Q1 2026 per AKTX's latest filing, from -$3.0 million in the prior quarter.
• Over the last five years, Free Cash Flow for AKTX reached as high as -$1.5 million in Q3 2024 and fell as low as -$4.9 million in Q2 2024.
• A 4-year average of -$3.2 million and a median of -$3.0 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2024 — Free Cash Flow surged 51.83% — and 2025, when it slumped 43.17%.
• Year by year, Free Cash Flow stood at -$4.4 million in 2023, then jumped by 51.83% to -$2.1 million in 2024, then sank by 43.17% to -$3.0 million in 2025, then climbed by 18.18% to -$2.5 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$2.5 million, -$3.0 million, and -$2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.